Company intelligence / Profile preview

Telix Pharmaceuticals Limited

North Melbourne, Victoria, Australiatelixpharma.com ↗

Ownership: Public · TLX
Employees: ~234
Development stage: Commercial

Overview

Telix has received global regulatory approvals from the Australian TGA, U.S. FDA, and Health Canada for its prostate cancer imaging agent Illuccix®. The company has 18 clinical trials underway worldwide across various disease areas[1][4].

Therapeutic areas: OncologyRare DiseasesHematology
Modalities: RadiopharmaceuticalsTheranosticsTargeted radiation therapy
Industry: Biotech

Drug pipeline

41 assets

gallium Ga-68 gozetotide (Novartis)

Approved

40 more assets in the full pipeline.

Request access →

Financials

Market cap: $4.2B
Total revenue: $691.4M
Enterprise value: $4.7B

Beyond the preview

Go deeper on Telix Pharmaceuticals Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Telix Pharmaceuticals Limited.

Explore the full profile